Multiomic Diagnostics in Youth With Psychosis
ConditionPsychosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age7-17
SponsorRady Pediatric Genomics & Systems Medicine Institute
About this trial
Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatment for future patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Child/adolescent admitted to the Rady Children's CAPS with symptoms of first break psychosis
Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed genetically related to a patient participant.
Disqualifiers
Already received any prior whole genome sequencing or exome sequencing.
Unable to approach the family or patient for enrollment.
Unable to obtain informed consent.
They are known to not be genetically related to the child/adolescent patient participant
Trial design
Design model
Single group
Treatments tested in this trial
Genetic: Genomic sequencing and molecular diagnostic results, if any.
GeneticGenomic sequencing results may be used for diagnosis and treatment of participants.
Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Diagnostic testWhole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
Treatment groups
15 Participants
are divided into 1 treatment groupGroup A: Enrollees - WGSExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Diagnostic rate of brain reactive autoantibodies
Diagnostic rate of brain reactive autoantibodies via genomic and whole human proteome programmable phage display immunoprecipitation sequencing (PhIP-Seq)
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov